NASDAQ:ETON

Eton Pharmaceuticals Stock Forecast, Price & News

$5.39
-0.26 (-4.60 %)
(As of 07/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.37
$5.68
50-Day Range
$5.39
$8.85
52-Week Range
$5.21
$10.30
Volume124,380 shs
Average Volume380,546 shs
Market Capitalization$132.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
30 days | 90 days | 365 days | Advanced Chart
Receive ETON News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Eton Pharmaceuticals logo

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.05 out of 5 stars

Medical Sector

255th out of 2,218 stocks

Pharmaceutical Preparations Industry

119th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions

Is Eton Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Eton Pharmaceuticals stock.
View analyst ratings for Eton Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Eton Pharmaceuticals?

Wall Street analysts have given Eton Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eton Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Eton Pharmaceuticals?

Eton Pharmaceuticals saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 1,390,000 shares, a drop of 22.8% from the June 15th total of 1,800,000 shares. Based on an average trading volume of 633,700 shares, the short-interest ratio is presently 2.2 days. Currently, 6.9% of the company's shares are sold short.
View Eton Pharmaceuticals' Short Interest
.

When is Eton Pharmaceuticals' next earnings date?

Eton Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Eton Pharmaceuticals
.

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its quarterly earnings results on Thursday, May, 13th. The company reported $0.19 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.19. The company earned $11.90 million during the quarter, compared to analyst estimates of $12.05 million.
View Eton Pharmaceuticals' earnings history
.

How has Eton Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Eton Pharmaceuticals' stock was trading at $4.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ETON shares have increased by 28.3% and is now trading at $5.39.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ETON?

2 brokers have issued 1-year target prices for Eton Pharmaceuticals' shares. Their forecasts range from $11.00 to $14.00. On average, they expect Eton Pharmaceuticals' share price to reach $12.50 in the next year. This suggests a possible upside of 131.9% from the stock's current price.
View analysts' price targets for Eton Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eton Pharmaceuticals' key executives?

Eton Pharmaceuticals' management team includes the following people:
  • Mr. Sean E. Brynjelsen, Pres, CEO & Director (Age 49, Pay $705.93k)
  • Mr. W. Wilson Troutman CPA, CFO, Treasurer & Sec. (Age 67, Pay $396.48k)
  • Mr. Paul Stickler, Sr. VP of Sales & Marketing
  • Ms. Bharathi Devarakonda, Sr. VP of Regulatory Affairs & Product Devel.
  • Ms. Ingrid Hoos, Sr. VP of Regulatory Affairs
  • Mr. Scott Grossenbach, VP of Sales & Marketing
  • Mr. David Krempa CFA, VP of Bus. Devel.

Who are some of Eton Pharmaceuticals' key competitors?

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an initial public offering (IPO) on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation acted as the underwriter for the IPO.

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $5.39.

How much money does Eton Pharmaceuticals make?

Eton Pharmaceuticals has a market capitalization of $132.10 million and generates $40,000.00 in revenue each year. The company earns $-27,970,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does Eton Pharmaceuticals have?

Eton Pharmaceuticals employs 16 workers across the globe.

What is Eton Pharmaceuticals' official website?

The official website for Eton Pharmaceuticals is www.etonpharma.com.

Where are Eton Pharmaceuticals' headquarters?

Eton Pharmaceuticals is headquartered at 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.